Related Experiment Video

Updated: Mar 30, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.9K

miR-122 inhibits cancer cell malignancy by targeting PKM2 in gallbladder carcinoma

Wei Lu1,2, Yijian Zhang1,3, Linzhu Zhou4

  • 1Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine, 1665 Kongjiang Road, Shanghai, 200092, People's Republic of China.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|November 8, 2015
PubMed

Insights

MicroRNA-122 (miR-122) is significantly decreased in gallbladder cancer (GBC). Restoring miR-122 levels inhibits GBC cell proliferation, invasion, and metastasis, suggesting its therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Gallbladder cancer (GBC) is a lethal digestive system malignancy.
  • MicroRNAs (miRs) are emerging as potential therapeutic targets for cancers.
  • The role of miR-122 in GBC warrants investigation.

Purpose of the Study:

  • To investigate the expression of miR-122 in GBC.
  • To evaluate the antitumor effects of miR-122 in GBC.
  • To identify the molecular targets of miR-122 in GBC.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) for miR-122 expression analysis.
  • Transfection with miR-122 mimics to upregulate expression.
  • Cell function assays (CCK8, flow cytometry, wound healing, migration, invasion).
  • Bioinformatic prediction (TargetScan) and experimental validation (Western blot, luciferase assay) of target genes.

Main Results:

  • miR-122 expression was significantly decreased in GBC tissues and cell lines.
  • Exogenous miR-122 introduction suppressed GBC cell proliferation, invasion, and metastasis.
  • PKM2 was identified as a direct target gene of miR-122 in GBC.
  • miR-122 inhibited TGF-β-induced epithelial-mesenchymal transition (EMT) by downregulating PKM2.

Conclusions:

  • miR-122 functions as a tumor suppressor in GBC.
  • miR-122 targets PKM2, impacting GBC cell behavior and EMT.
  • miR-122 represents a promising therapeutic candidate for GBC treatment.
Keywords:
Gallbladder carcinomaMalignantPKM2miR-122

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.4K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K